Lee L S
Zhonghua Min Guo Wei Sheng Wu Ji Mian Yi Xue Za Zhi. 1982 Aug;15(3):202-11.
Serum anti-thyroglobulin antibody (TgAb) and anti-thyroid microsomal antibody (McAb) in 213 cases of thyroid disorders and 32 cases of non-thyroid disorders were studied. The antibodies were checked by commercial tanned red cell hemagglutination kits (Thymune-T and Thymune-M) purchased from Wellcome Reagents, Limited, England. The positive rates of TgAb and McAb in patients with untreated toxic diffuse goiter (45 cases) were 25.6% and 74.4%, respectively; 22.2% and 44.4% in toxic diffuse goiter on antithyroid therapy (36 cases); 42.9% and 71.4% in hyperthyroidism after thyroidectomy (7 cases); 60% and 80% in Hashimoto's thyroiditis (10 cases) and 100% and 50% in idiopathic primary hypothyroidism (2 cases). In hyperthyroidism and Hashimoto's thyroiditis, the positive rates of McAb were much higher than those of TgAb. The positive rates of TgAb and McAb in non-toxic nodular goiter were 11.7% and 10.4%, respectively; 6.1% and 3.0% in non-toxic diffuse goiter and 3.1% and 3.1% in non-thyroid disorders, There were 13 cases whose TgAb titers were 80 x (dilution factor) or higher and 25 cases whose McAb titers were 1600 x or higher. All of them belonged to the autoimmune thyroid diseases. It is, therefore, concluded that patients with autoimmune thyroid diseases have not only higher positive rates of TgAb and McAb but also higher titers of such antibodies, and determinations of TgAb and McAb by using the tanned red cell hemagglutination technique are of help in the diagnosis of autoimmune thyroid diseases.
对213例甲状腺疾病患者和32例非甲状腺疾病患者的血清抗甲状腺球蛋白抗体(TgAb)和抗甲状腺微粒体抗体(McAb)进行了研究。这些抗体采用从英国威康试剂有限公司购买的商用鞣酸红细胞血凝试剂盒(Thymune - T和Thymune - M)进行检测。未经治疗的毒性弥漫性甲状腺肿患者(45例)中TgAb和McAb的阳性率分别为25.6%和74.4%;接受抗甲状腺治疗的毒性弥漫性甲状腺肿患者(36例)中分别为22.2%和44.4%;甲状腺切除术后甲亢患者(7例)中分别为42.9%和71.4%;桥本甲状腺炎患者(10例)中分别为60%和80%;特发性原发性甲状腺功能减退症患者(2例)中分别为100%和50%。在甲亢和桥本甲状腺炎中,McAb的阳性率远高于TgAb。非毒性结节性甲状腺肿中TgAb和McAb的阳性率分别为11.7%和10.4%;非毒性弥漫性甲状腺肿中分别为6.1%和3.0%;非甲状腺疾病中分别为3.1%和3.1%。有13例患者的TgAb滴度为80×(稀释倍数)或更高,25例患者的McAb滴度为1600×或更高。所有这些患者均属于自身免疫性甲状腺疾病。因此,得出结论:自身免疫性甲状腺疾病患者不仅TgAb和McAb的阳性率较高,而且此类抗体的滴度也较高,采用鞣酸红细胞血凝技术检测TgAb和McAb有助于自身免疫性甲状腺疾病的诊断。